COVID-19 in PH patients: a reference center survey

70 patients with PH had confirmed COVID-19

Of these, 44 patients were hospitalized

47 centres

28 countries

11 needed ICU care

13 died

Centres by number of cases:
- no cases
- 1 case
- 2-4 cases
- ≥5 cases
- >10 cases
Follow up of PAH/CTEPH patients during the COVID-19 pandemic

Number of patients (n=70)
Number of centres (n=47)
Age distribution (years)

Number of patients (n=70)

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-19</td>
<td>1</td>
</tr>
<tr>
<td>20-29</td>
<td>7</td>
</tr>
<tr>
<td>30-39</td>
<td>7</td>
</tr>
<tr>
<td>40-49</td>
<td>8</td>
</tr>
<tr>
<td>50-59</td>
<td>19</td>
</tr>
<tr>
<td>60-69</td>
<td>10</td>
</tr>
<tr>
<td>70-79</td>
<td>14</td>
</tr>
<tr>
<td>80-89</td>
<td>4</td>
</tr>
</tbody>
</table>

Number of centres (n=47)
Pulmonary hypertension treatment

- Monotherapy
- Bitherapy
- Tritherapy (oral)
- Tritherapy (parenteral PG\textsubscript{I2})

Number of patients (n=56)
Number of centres (n=16)
CTEPH patients

- 8% awaiting for BPA
- 17% awaiting for PEA
- 8% BPA delayed#
- 67% inoperable/post-operative residual PH

#Because of pandemic logistic situation
None had PEA delayed because of pandemic logistic situation

Number of patients (n=12)
Number of centres (n=6)
COVID-19 presenting symptoms

- Pneumonia: 34
- Fever only: 17
- Upper respiratory tract infection: 8
- Other: 8
- PH exacerbation/RHF: 3
- Anosmia/ageusia: 2
- Asymptomatic: 2

No VTE or hemoptysis

*other: myalgia, dyspnoea or cough

Symptoms duration: 6.0 days (range: 1-36)
COVID-19 diagnostic examinations

Number of patients (n=66)

- nasopharyngeal swab (PCR): 49
- low dose CT: 10
- clinical suspicion only: 7

Number of centres (n=18)
COVID-19 CT characteristics

Number of patients (n=46)
Number of centres (n=18)

- Typical COVID: 25
- Atypical: 3
- Not done: 18
COVID-19 hospitalisation

- Ward: 11 patients
- Back home: 19 patients
- ICU: 4 patients
- Other*: 29 patients

*other: nursing home, intermediate care unit, social-sanitary centre

Hospital stay: 3.4 days (range: 2-32)

Number of patients (n=63)
Number of centres (n=14)
COVID-19 hospitalisation

<table>
<thead>
<tr>
<th>Location</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>in your hospital</td>
<td>23</td>
</tr>
<tr>
<td>in a local hospital</td>
<td>15</td>
</tr>
<tr>
<td>in another expert center</td>
<td>11</td>
</tr>
</tbody>
</table>

Number of patients (n=49)
Number of centres (n=16)
COVID-19 respiratory support

- Oxygen: 37 patients
- High-flow nasal cannula: 8 patients
- Non-invasive ventilation: 1 patient
- Invasive ventilation: 7 patients
- No treatment: 12 patients
- No patient reported on ECMO

Number of patients (n=65)
Number of centres (n=18)

#continuous positive airway pressure (cPAP) / bi-level positive airway pressure (biPAP)
COVID-19 pharmacological treatment

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Number of patients (n=70*)</th>
<th>Number of centres (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>antibiotics/azithromycin</td>
<td>28</td>
<td>14</td>
</tr>
<tr>
<td>hydrochloroquine/chloroquine</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>lopinavir/ritonavir</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>other*</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>itraconazol</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

*Patients could have received more than one treatment

*other: tocilizumab, methylprednisolone, mycophenolate, favipiravir and rituximab
THANKS TO


Slide design by Dilara Eren & Rozenn Quarck